288 related articles for article (PubMed ID: 12181740)
41. Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling.
Morgan MA; Dolp O; Reuter CW
Blood; 2001 Mar; 97(6):1823-34. PubMed ID: 11238126
[TBL] [Abstract][Full Text] [Related]
42. Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin.
Lee MW; Kim DS; Min NY; Kim HT
Int J Cancer; 2008 May; 122(10):2380-4. PubMed ID: 18224693
[TBL] [Abstract][Full Text] [Related]
43. Baicalein increases the expression and reciprocal interplay of RUNX3 and FOXO3a through crosstalk of AMPKα and MEK/ERK1/2 signaling pathways in human non-small cell lung cancer cells.
Zheng F; Wu J; Zhao S; Luo Q; Tang Q; Yang L; Li L; Wu W; Hann SS
J Exp Clin Cancer Res; 2015 May; 34(1):41. PubMed ID: 25948105
[TBL] [Abstract][Full Text] [Related]
44. Phosphoprotein analysis reveals MEK inhibition as a way to target non-small cell lung cancer tumor initiating cells.
Lundholm L; Hååg P; Juntti T; Lewensohn R; Viktorsson K
Int J Radiat Biol; 2014 Aug; 90(8):718-26. PubMed ID: 24646078
[TBL] [Abstract][Full Text] [Related]
45. The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis.
Mandic A; Viktorsson K; Heiden T; Hansson J; Shoshan MC
Melanoma Res; 2001 Feb; 11(1):11-9. PubMed ID: 11254111
[TBL] [Abstract][Full Text] [Related]
46. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.
Steelman LS; Franklin RA; Abrams SL; Chappell W; Kempf CR; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo P; Ruvolo V; Evangelisti C; Martelli AM; McCubrey JA
Leukemia; 2011 Jul; 25(7):1080-94. PubMed ID: 21494257
[TBL] [Abstract][Full Text] [Related]
47. Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells.
Zheng H; Liu A; Liu B; Li M; Yu H; Luo X
Cancer Lett; 2010 Nov; 297(1):117-25. PubMed ID: 20554106
[TBL] [Abstract][Full Text] [Related]
48. Activation of Akt1 by human 5-hydroxytryptamine (serotonin)1B receptors is sensitive to inhibitors of MEK.
Hsu EH; Lochan AC; Cowen DS
J Pharmacol Exp Ther; 2001 Aug; 298(2):825-32. PubMed ID: 11454948
[TBL] [Abstract][Full Text] [Related]
49. The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines.
Mattingly RR; Kraniak JM; Dilworth JT; Mathieu P; Bealmear B; Nowak JE; Benjamins JA; Tainsky MA; Reiners JJ
J Pharmacol Exp Ther; 2006 Jan; 316(1):456-65. PubMed ID: 16239399
[TBL] [Abstract][Full Text] [Related]
50. MEK inhibition enhances paclitaxel-induced tumor apoptosis.
MacKeigan JP; Collins TS; Ting JP
J Biol Chem; 2000 Dec; 275(50):38953-6. PubMed ID: 11038347
[TBL] [Abstract][Full Text] [Related]
51. Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.
Della Corte CM; Ciaramella V; Di Mauro C; Castellone MD; Papaccio F; Fasano M; Sasso FC; Martinelli E; Troiani T; De Vita F; Orditura M; Bianco R; Ciardiello F; Morgillo F
Oncotarget; 2016 Jan; 7(4):4265-78. PubMed ID: 26673006
[TBL] [Abstract][Full Text] [Related]
52. Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts.
Lunghi P; Tabilio A; Dall'Aglio PP; Ridolo E; Carlo-Stella C; Pelicci PG; Bonati A
Leukemia; 2003 Sep; 17(9):1783-93. PubMed ID: 12970778
[TBL] [Abstract][Full Text] [Related]
53. Beauvericin-induced cell apoptosis through the mitogen-activated protein kinase pathway in human nonsmall cell lung cancer A549 cells.
Lu CL; Lin HI; Chen BF; Jow GM
J Toxicol Sci; 2016; 41(3):429-37. PubMed ID: 27193734
[TBL] [Abstract][Full Text] [Related]
54. Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition.
Mayes PA; Degenhardt YY; Wood A; Toporovskya Y; Diskin SJ; Haglund E; Moy C; Wooster R; Maris JM
Int J Cancer; 2013 Feb; 132(3):E149-57. PubMed ID: 22948716
[TBL] [Abstract][Full Text] [Related]
55. [Expression and significance of MAPK/ERK in the specimens and cells of epithelial ovarian cancer].
Jiang XL; Gao JC; Jiang L; Zhang PX; Kang TJ; Sun Q; Qi WJ; Zhang QP; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2019 Aug; 54(8):541-547. PubMed ID: 31461811
[No Abstract] [Full Text] [Related]
56. Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance.
McCubrey JA; Abrams SL; Ligresti G; Misaghian N; Wong EW; Steelman LS; Bäsecke J; Troppmair J; Libra M; Nicoletti F; Molton S; McMahon M; Evangelisti C; Martelli AM
Leukemia; 2008 Nov; 22(11):2080-90. PubMed ID: 18685611
[TBL] [Abstract][Full Text] [Related]
57. MEK inhibitors for the treatment of non-small cell lung cancer.
Han J; Liu Y; Yang S; Wu X; Li H; Wang Q
J Hematol Oncol; 2021 Jan; 14(1):1. PubMed ID: 33402199
[TBL] [Abstract][Full Text] [Related]
58. Noncatalytic function of ERK1/2 can promote Raf/MEK/ERK-mediated growth arrest signaling.
Hong SK; Yoon S; Moelling C; Arthan D; Park JI
J Biol Chem; 2009 Nov; 284(48):33006-18. PubMed ID: 19805545
[TBL] [Abstract][Full Text] [Related]
59. Thyroid hormone promotes serine phosphorylation of p53 by mitogen-activated protein kinase.
Shih A; Lin HY; Davis FB; Davis PJ
Biochemistry; 2001 Mar; 40(9):2870-8. PubMed ID: 11258898
[TBL] [Abstract][Full Text] [Related]
60. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach.
Yoon YK; Kim HP; Han SW; Oh DY; Im SA; Bang YJ; Kim TY
Mol Carcinog; 2010 Apr; 49(4):353-62. PubMed ID: 20358631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
